What we're building, in our own words.

Why I built a portal instead of another website.

The peptide market has a sourcing problem the customer never sees. Most buyers work through one of a small number of US-based brokers who themselves source through unverified Chinese channels; clinical pharmacies, research operators, and sophisticated bulk-API customers all end up in the same funnel. The buyer pays a markup for opacity. PeptidesBySwomp exists because that arrangement is bad for everyone except the broker.

The structural choice we are making is to operate as an insider in the Chinese pharmaceutical ecosystem through a partner network, not as an importer buying through a broker. That sounds like a small distinction; it is not. An insider negotiates on price against a known cost structure rather than a marked-up reseller quote. An insider sits in on the audit instead of receiving a summary of it. An insider can trace a lot back to a real facility audited by real people, and can name, when asked under NDA, the questions that audit asked and the answers it got. A broker can do none of those things, and the buyer who works through a broker inherits all of the broker's blind spots.

This is also why the portal is gated and credentialed-only. I am not manufacturing exclusivity. I am operating honestly inside the only posture that works in this category in 2026: research-use-only, sold to credentialed buyers who can stand behind what they are buying it for. A public storefront with a checkout button would not be a more transparent version of this business; it would be a less honest one.

The buyer pays a markup for opacity. PeptidesBySwomp exists because that arrangement is bad for everyone except the broker.

Some commitments, since this is the first thing I'm publishing. Within ninety days I will publish every third-party audit report we receive, redacted only for supplier identity. I will publish three quarterly letters on the state of our supply chain, including the failures: this one and two more. I will keep my line open to every Clinical Partner on this portal, by name, for as long as I am the founder. Hold me to it.

On the question of why we don't name our suppliers.

This site is built on the claim that PeptidesBySwomp is more transparent than the broker model. Every lot ships with a 14-test COA. The audit framework is public. The methodology is documented. And yet we don't name our suppliers. I want to address that directly, because I read it the way a careful buyer would read it: as a contradiction.

It is a trade-off, not a contradiction, and it deserves an honest accounting. Supplier identity protection is not supplier opacity. A buyer working with us gets the lot, the COA, the test methodology, the chain of custody, and the audit framework that produced the facility we sourced from. What a buyer does not get, on the public site, is the name on the door of the partner facility. Everything else about the lot is verifiable.

There are two reasons for this, and both are load-bearing. The first is supplier exclusivity. The relationships we are building compete on the basis of being non-public. Naming a partner publicly invites every other US peptide buyer to engage them directly, which erodes the partner's pricing power and ours, and over time degrades the relationship into a transactional one. The second is supplier protection. In the current Chinese pharmaceutical regulatory environment, public attribution to a US-facing peptide brand is not always something a partner wants on their record, and it is not my call to make for them.

For the buyer who needs to know more anyway: any qualified Clinical Partner can request, under NDA, a redacted audit summary on the specific SKUs they are sourcing. That is the right granularity for that conversation. The public site is not.

This is one of the trade-offs of operating in this category seriously. Most peptide vendors don't talk about it because most peptide vendors aren't operating seriously. I would rather name the trade-off out loud than pretend it isn't there.

What we're trying to build, in plain words.

Before any of the catalog or the Pulse graph or the COA library, here is what we are actually trying to do. The peptide market is in the middle of a structural transformation: GLP-1 weight loss agonists in clinical practice, longevity research moving out of academic labs, regenerative peptides showing up in compounding workflows that did not exist five years ago. The infrastructure to source these compounds at credentialed-buyer scale, honestly, does not exist yet outside of broker chains. PeptidesBySwomp is being built to fill that gap.

What that looks like in practice is four things. A credentialed-buyer portal, gated to qualified operators. A curated catalog that is narrower than it could be on purpose, paired with real third-party COAs on every lot. A sourcing operation that works inside the Chinese pharmaceutical ecosystem through a partner network rather than through a US broker. And a posture that treats RUO compliance as load-bearing rather than performative; not a banner at the bottom of the page, but the actual shape of how we sell, who we sell to, and what we say while we are doing it.

This is not for everyone, and that is intentional. It is not retail. It is not for the casual buyer or the gray-market reseller. It is for compounding pharmacies, IRB-approved research programs, qualified bulk-API buyers, and clinical partners who need a supply chain they can stake their license on. If that is not you, we are not the right fit, and I would rather say so on the first page than waste anyone's time.

If it is you, the invitation is open. The application is on the site. My email is in the footer and it actually reaches me. If you are building something serious in this space and want to talk about it before applying, write. I would rather have one good conversation than ten generic ones.